Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2022 Jun 22:2022.06.21.22276724. [Version 1] doi: 10.1101/2022.06.21.22276724

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Figure 1. — Comparison of 7- and 30-day risks for COVID-19 rebound in patients treated with Paxlovid or with Molnupiravir before and after propensity-score matching for demographics, adverse socioeconomic determinants of health, comorbidities, immunosuppressant usage, organ transplantation, and EHR-documented COVID-19 vaccination status. Rebound outcomes (COVID-19 infections, COVID-19 related symptoms, and hospitalizations) were followed for 7 days (from 2 through 8 days after the last day of treatments) and for 30 days (from 2 through 31 days after the last day of treatments).